Big Tech Acquisitions and Product Discontinuation
Journal of Competition Law & Economics · 13.09.2024 · 20 (3) · 246-263
DOI: 10.1093/joclec/nhae010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Competition Law & Economics, online erschienen am 25.07.2024. Verfasst von Axel Gautier und 1 weiteren Autor:innen. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
The five largest firms by market capitalization, Alphabet, Amazon, Apple, Meta, and Microsoft have massively acquired companies during the last decades, mainly but not exclusively young tech startups. Interestingly, most of the acquired products are discontinued post-acquisition. In this paper, we have collected data on the acquisitions of the big techs for a period of 7 years spanning from 2015 to 2021 and we analyze the evolution of the acquired firms’ products post-acquisition. To analyze the decision to continue or not a product post-acquisition, we classify acquisition in four categories: products that are still offered under their initial brand name, products integrated in the acquirer’s ecosystem, products that are no longer available and products that are killed by the acquirer. We use these classifications to provide detailed information and statistics on the discontinuation decision of the acquiring firm and we run Probit estimation to explain their determinants.
Zitieren
APA
Gautier, A., & Maitry, R. (2024). Big Tech Acquisitions and Product Discontinuation. Journal of Competition Law & Economics, 20(3), 246-263. https://doi.org/10.1093/joclec/nhae010
Vancouver
Gautier A, Maitry R. Big Tech Acquisitions and Product Discontinuation. Journal of Competition Law & Economics. 2024;20(3):246-263. doi:10.1093/joclec/nhae010
BibTeX
@article{Gautier2024,
author = {Gautier, Axel and Maitry, Robert},
title = {Big Tech Acquisitions and Product Discontinuation},
journal = {Journal of Competition Law & Economics},
year = {2024},
volume = {20},
number = {3},
pages = {246--263},
doi = {10.1093/joclec/nhae010}
}
EUVIMED